Embryos Turned into 'Personalized Stem Cell Lines'
A company offers to turn leftover embryos into designer stem cell treatments.
Aug. 14, 2007 — -- Following in vitro fertilization procedures, families have traditionally had three options for unused embryos that were fertilized but never implanted into a woman's womb. They could give them to sterile couples, donate them to research facilities or discard them.
StemLifeLine, a California-based biotechnology company, is now offering a controversial but potentially life-saving fourth option.
StemLifeLine allows families to "develop" remaining embryos into "personalized stem cell lines," the first theoretical step in creating cures for a host of debilitating and deadly diseases.
"The embryonic stem cells could be used to develop cures for diseases like diabetes, lymphoma and Parkinson's," said Dr. Russell Foulk, director of two of the four fertility clinics putting patients in touch with StemLifeLine and a member of the company's board of directors.
StemLifeLine is betting that the promise of stem cells will encourage people to buy its services. However, since so much of that potential remains unknown, some medical ethicists worry the company is selling empty promises.
"It's a gimmick and many of the claims rest on hot air," said Arthur Caplan, professor of bioethics at the University of Pennsylvania.
Caplan said StemLifeLine was "offering a unique product" but questioned the ethics of selling people stem cell lines as if they were a guaranteed cure.
"In fact any clinic can do it, just like any clinic can freeze embryos. The problem is no one has made anything useful out of stem cells," he said.
The promise of stem cells lies in their ability to grow into specialized cells like those found in the brain or bone marrow. Stem cell lines are those cells that have been removed from fertilized embryos and have the potential to become differentiated cells.
StemLifeLine is offering what they call "personalized stem cell lines." Those lines could then be turned into treatments that could be specially designed genetic matches just for donors, Foulk said.